Skip to main content Back to Top
Advertisement

2/4/2024

Hydromorphone Immediate-Release Oral Presentations

Products Affected - Description

    • Dilaudid oral immediate release tablet, Rhodes, 2 mg, bottle, 100 count, NDC 42858-0122-01
    • Dilaudid oral immediate release tablet, Rhodes, 8 mg, bottle, 100 count, NDC 42858-0338-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Mallinckrodt, 2 mg, bottle, 100 count, NDC 00406-3243-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Mallinckrodt, 4 mg, bottle, 100 count, NDC 00406-3244-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Mallinckrodt, 8 mg, bottle, 100 count, NDC 00406-3249-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Rhodes, 2 mg, bottle, 100 count, NDC 42858-0301-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Rhodes, 4 mg, bottle, 100 count, NDC 42858-0302-01
    • Hydromorphone Hydrochloride oral immediate release tablet, Rhodes, 8 mg, bottle, 100 count, NDC 42858-0303-01
    • Hydromorphone Hydrochloride oral solution, Rhodes, 1 mg/mL, 473 mL bottle, NDC 42858-0304-16
    • Hydromorphone Hydrochloride oral tablet, Rhodes, bottle, 500 count, NDC 42858-0302-50

Reason for the Shortage

    • Rhodes has hydromorphone tablets on back order due to DEA quota/active ingredient exhaustion.
    • Rhodes did not provide a reason for the shortage of Dilaudid oral presentations.
    • Mallinckrodt is actively manufacturing hydromorphone tablets. Wholesalers may be allocating product.

Available Products

    • Dilaudid oral immediate release tablet, Rhodes, 4 mg, bottle, 100 count, NDC 42858-0234-01
    • Dilaudid oral immediate release tablet, Rhodes, 4 mg, bottle, 500 count, NDC 42858-0234-50
    • Dilaudid oral solution, Rhodes, 1 mg/mL, 473 mL bottle, NDC 42858-0416-16
    • Hydromorphone Hydrochloride oral immediate release tablet, Rhodes, 2 mg, unit-dose blister pack, 100 count, NDC 42858-0301-25
    • Hydromorphone Hydrochloride oral immediate release tablet, Rhodes, 4 mg, unit-dose blister pack, 100 count, NDC 42858-0302-25

Estimated Resupply Dates

    • Mallinckrodt is actively manufacturing hydromorphone tablets. Wholesalers are allocating all presentations.
    • Rhodes has hydromorphone 2 mg tablets in 100 count bottles, 4 mg tablets in 100 count bottles, 4 mg tablets in 500 count bottles, 8 mg tablets in 100 count bottles, and 1 mg/mL oral solution on back order. The company cannot estimate a release date for the 4 mg tablets in 100 count bottles and 500 count bottles and the 1 mg/mL oral solution. The 2 mg tablets in 100 count bottles and 8 mg tablets in 100 count bottles are expected to release in late-March 2024.
    • Rhodes has Dilaudid 2 mg tablets in 100 count bottles and 8 mg tablets in 100 count bottles on back order and the company cannot estimate a release date.

Updated

Updated February 4, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created December 15, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.